HJAR Sep/Oct 2020

26 SEP / OCT 2020  I  HEALTHCARE JOURNAL OF ARKANSAS   Healthcare Briefs and treatment of workplace injuries; and other medical evaluations as required. Additional ser- vices include annual physical exams, immuniza- tions, lab services, rehabilitation evaluation, respi- ratory screening, and substance abuse services. UAMSWinthrop P. Rockefeller Cancer Institute Joins KIYATECClinical Study of Test to Predict Pre-Treatment, Patient-Specific Response to Ovarian Cancer Drugs KIYATEC, Inc. announced that the Winthrop P. Rockefeller Cancer Institute at the University of Arkansas for Medical Sciences (UAMS) has joined the growing roster of institutions partici- pating in its 3D-PREDICT clinical study to validate the company’s test as a patient-specific predictor of response to recommended drug therapies for patients with ovarian cancer. “Ovarian cancer patients and clinicians do not have the luxury of time to experiment with drug therapies they don’t know will work, so we devel- oped our investigational ovarian cancer drug response profile to help optimize therapeutic decision-making over the course of the disease,” said Matthew Gevaert, CEO of KIYATEC. “We are delighted to welcome UAMS to the 3D-PREDICT study as we endeavor to deliver on the promise of pre-treatment, patient-specific drug response profiling for ovarian cancer.” 3D-PREDICT is a prospective, open-label, non- interventional study to validate KIYATEC’s ovar- ian cancer drug response profile, which leverages the company’s ex vivo 3D cell culture technology platform to assess pre-treatment, patient-specific response to a panel of 11 drugs most commonly used to treat patients with newly diagnosed or recurrent ovarian cancer.  “The Winthrop P. Rockefeller Cancer Institute is proud to offer 3D-PREDICT to our ovarian can- cer patients. It is our hope that this trial will help develop a method to assist us in determining which drugs will most benefit individual patients and get them on the most effective treatment as quickly as possible,” said Michael Birrer, MD, PhD, vice chancellor and director of the Cancer Institute. KIYATEC leverages its proprietary ex vivo 3D cell culture technology platforms to accurately model and predict response to approved and investigational cancer drugs targeting a spectrum of solid tumors. The company’s clinical services business is currently engaged in the validation of clinical assays as well as investigator-initiated studies in ovarian cancer, breast cancer, glioblas- toma and rare tumors, in its CLIA-certified labo- ratory. The company’s drug development services business works in partnership with leading bio- pharmaceutical companies to unlock response dynamics for their investigational drug candidates across the majority of solid tumor types. George and Linda Gleason Foundation Gives $100,000 for UAMS Psychiatric Research Institute, Department of Neurology The George and Linda Gleason Foundation has given $100,000 to the University of Arkansas for Medical Sciences (UAMS), split evenly among the Department of Neurology in the College of Medi- cine and the Psychiatric Research Institute. The Gleasons were on hand June 19 to pres- ent a check to R. Lee Archer, MD, chair of the Department of Neurology, and G. Richard Smith, MD, director of the Psychiatric Research Institute and chair of the Department of Psychiatry in the UAMS College of Medicine. George Gleason has served for more than 40 years as chairman and chief executive officer of Bank OZK and its predecessor institutions. “The George and Linda Gleason Foundation is very pleased to support the UAMS Department of Neurology and the Psychiatric Research Institute in their delivering world-class care to the citizens of Arkansas,” said George Gleason. “The men who lead these two units are excep- tional physicians and outstanding human beings,” said Linda Gleason. “Dr. Lee Archer and Dr. Rich- ard Smith are well-known for having an unparal- leled commitment to personal care and concern for their patients and their teammates.” A fixture at UAMS for more than 30 years, Archer provides nationally recognized care for Arkansans with multiple sclerosis (MS), while teaching and mentoring future neurologists. He has earned the admiration of his patients, stu- dents, residents, and colleagues. Archer is a neurologist and professor in the UAMS College of Medicine. He also holds the Major and Ruth Nodini Chair in Neurology, a $1.5 million endowment that supports his clini- cal care, multiple sclerosis research, and educa- tional programs. “This gift will be used to support our blossom- ing research efforts in neurology that are directed towards neurodegenerative diseases, like Parkin- son’s Disease and Amyotrophic Lateral Sclerosis and autoimmune diseases like multiple sclerosis,” The Gleasons present a check for$100,00 to R. Lee Archer, MD, chair of the Department of Neurology, and G. Richard Smith, MD, director of the Psychiatric Research Institute and chair of the Department of Psychiatry in the UAMS College of Medicine.